Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat...

12
Submit your manuscripts at http://www.hindawi.com

Transcript of Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat...

Page 1: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Submit your manuscripts at

http://www.hindawi.com

Page 2: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

I N T E R N AT I ON A L

SCIENCE & ENGINEERING

V I S U A L I Z A T I O N

C H A L L E N G E

Call for Entries

ENTRY DEADLINE:

SEPTEMBER 30, 2013

science & engineering’s

most powerful

statements are not

made from words alone

You are invited to submit an entry to this year’s International Science

& Engineering Visualization Challenge, cosponsored by the National

Science Foundation and AAA’s journal Science.

Entry categories include: Photography, Illustration,

Posters and Graphics, Games & Apps, and Video.

Winning entries will be published in a special

section of a February 2014 print issue of Science

and ScienceMag.org, and NSF’s web site.

ENTRY DEADLINE: SEPTEMBER 30, 2013

For entry forms, rules, and more information, go to:

www.nsf.gov/news/scivis

Award Categories

• Photography

• I l lustrat ion

• Posters & Graphics

• V ideo

• Games & Apps

Page 3: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Adjacent to Tokyo International (Haneda) Airport lies a unique 40-hect-

are science and technology innovation hub, the Kawasaki INnovation

Gateway (KING) SKYFRONT.The mission of this futuristic facility is to

find actionable solutions to issues in regenerative medicine, cancer treat-

ment, and the prevention ofëlifestyleí diseases such as obesity. Important-

ly, the Japanese government has designated the KING SKYFRONT to be

a special zone for international competitiveness development, bestowing

it special privileges including reduced corporate taxes and government-

backed financial support for projects launched there.

ìKING SKYFRONT is the first important step in establishing the To-

nomachi area of Kawasaki City as Asiaís Silicon Valley,î says Nobuhide

Kobayashi, executive director of the Coastal Area International Strategy

Office, Kawasaki City. ìWe are confident that the easy access provided by

Haneda Airport, in conjunction with the excellent research and develop-

ment infrastructure, will form the basis for unprecedented business op-

portunities growing out of innovative science, medicine, and technology.î

Kobayashi has reason to be confident. Kawasaki City, with its 1.4 million

inhabitants, is already home to many blue chip companies including Aji-

Kawasaki City: The KING SKYFRONT InnovationHub for 21st Century Life Science

ADVERTORIAL

intractable diseases. Notably, NanoCarrier is listed on theMothers (market

of the high-growth and emerging stocks) section of theTokyo Stock Ex-

change and valued at •100 billion (US$985 million).

Underscoring Kataokaís internationally recognized contributions to

innovative research in nanobiotechnology, he recently received support

from Japanís prestigious national Funding Program forWorld-Leading In-

novative Research and Development on Science andTechnology (FIRST)

program.With funding of •3.6 billion (US$35.7 million) over five years,Kataokaís team will address the following topics: (1)Treatment of cancer

stem cells using targeted drug delivery systems in which nanometer-sized

drug carriers are able to selectively bind to cancer cells; (2) Treatment

of neurological diseases such as Alzheimerís disease using functionalized

micelles capable of passing through the blood-brain barrier; (3) Develop-

ment of nanovaccines that can be stored for long periods of time at room

temperature; (4) Fusion of drug delivery platforms with medical devices

for minimally invasive ìchemical surgeryîósuch as ultrasonic waves that

activate drugs at specific places in the bodyóto reduce the length of hos-

pital stays for patients; and (5) Development of point-of-care diagnostic

devices, such as the use of portable nanofabricated systems to detect mi-

croRNAs and specific enzymes.

Kataoka emphasizes the importance of what he calls ësmart healthcare.í

ìReducing the time a patient stays in hospital would be a tremendous

contribution to society. I am confident that research at iCON can achieve

this.î As an example of how nanomedicine may eventually be used by

millions of people, Kataoka describes the development of the advanced

technology necessary to produce hybrid cars. ìThese cars require a lot of

expensive technology. But mass production has enabled cost reductions to

within the price range of millions of people worldwide. I predict a similar

scenario for nanomedicine.î

nomoto, Toshiba, Fujitsu, and NEC as well as other global brands that

have played a central role in the growth of Japanís economy over the last

century.

The KING SKYFRONT is at the heart of the Keihin Industrial Re-

gion, encompassing areas ofTokyo and Kanagawa Prefecture, and Haneda

Airport. This location offers unprecedented land, sea, and air access to

cities within Japan, and the international airport connects the area to

Asia, North America, and Europe. ìLife science is one of the strategic

areas for KING SKYFRONT,î says Kobayashi. ìWe envisage that visit-

ing scientists, medical doctors, and business people will be able to ar-

rive at Haneda in the morning, go directly from the airport to KING

SKYFRONT, participate in meetings, and return to their country on an

evening flight.î

In addition to the excellent technological infrastructure and access,

KING SKYFRONT is located within commuting distance of international

schools and medical clinics run by English-speaking cliniciansóimpor-

tant factors to consider for creating long-term collaborations with over-

seas partners.

Launch of the innovation

Center Of Nanomedicine

The innovation Center Of Nanomed-

icine (iCON) is set to be the flagship

of the KING SKYFRONT devel-

opment. With government startup

funding of approximately •3.5 bil-

lion (US$34.7 million), constructionon the project is due to start in 2013,

with a formal launch in 2014. Re-

search at the centerócarried out by groups from academia, industry, and

governmentówill address such diverse issues as the medico-economic

impact of aging populations, curbing the increasing cost of medical care,

improving point of care treatment, and establishing new medical markets

in developing countries.

Translation of research ideas to the marketplace and fabrication/manu-

facture are two of the main strategic pillars of the center, emphasizes Pro-

fessor Kazunori Kataoka of the University ofTokyo, who will be director

of research in nanomedicine at the center. ìThe KING SKYFRONT will

offer an open-innovation approach to meet our targets,î says Kataoka.

ìThe proximity of Haneda Airport, the availability of clean rooms and

related infrastructure for nanofabrication, industrial participation, and

professionals to advise on the commercial aspects of research are essential

ingredients for taking creative ideas from the laboratory to the market-

place. KING SKYFRONT can be viewed as a highly condensed version

of SiliconValley.î

Kataoka is no stranger to big ideas and translational research, having

launched the company NanoCarrier in 1996 to commercialize nanosized

micelles for targeted drug delivery for the treatment of cancer and other

Kazunori Kataoka

Page 4: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Laying the Foundations for a Global Innovation Hub

The Central Institute for Experimental Animals (CIEA)óinternationally

recognized for research on the use of induced pluripotent stem cells for

the treatment of spinal cord injuries and Alzheimerís diseaseówas the

first major research institute to move to KING SKYFRONT, transferring

its facilities in July 2011.

March 2013 saw the opening of the Life Science and Environment Re-

search Center (LiSE) to promote collaborative research in the life sci-

ences, and consisting of a multipurpose facility housing laboratories from

both Kawasaki City and the private sector.

In 2016, the Japanese National Institute of Health Sciences (NIHS) will

move from Tokyo to the KING SKYFRONT. The NIHS plays a central

role in regulatory science in Japan and at KING SKYFRONT it will es-

tablish global standards for new drugs and medical technology developed

by researchers there.

KING SKYFRONT has attracted attention from overseas companies

including Johnson and Johnson, which will establish an R&D and training

center onsite.

ìThe worldís life sciences community will

continue to ëorganicallyí lay the foundations for

a global innovation hub for research,î says Ko-

bayashi. ìItís an exciting time at Kawasaki City

as KING SKYFRONT evolves into a global base

for research in the 21st century.î

From Lab to Market

Technology transfer at iCON will be managed by two professors

from the University of Tokyo: Hiromichi Kimura, in charge of Phar-

maco-Business Innovation at the Graduate School of Pharmaceuti-

cal Sciences, and Tomohiro Anzai, a member of the Translational

Research Initiative.

Kimuraís academic background is in biochemistry. After graduat-

ing from the University of Tokyo, he joined a major life sciences-based

company in Japan before moving to the U.S. to complete an Master of

BusinessAdministration and Ph.D. at Stanford University. ìI now have my

own consultancy company as well as the post at the University ofTokyo,î

says Kimura. Anzai is also a graduate of the University of Tokyo where

he trained as a molecular biologist. He spent some time at a consultancy

company, because he ìwas interested in the commercialization of research

ideas,î before joining KING SKYFRONT.Anzai also works with the Uni-

versity ofTokyo Hospital on technology transfer.

Kimura andAnzai stress that the interdisciplinary nature of the projects

at KING SKYFRONT and iCON will require good communication skills

between project members. ìWe will not only have people from differ-

ent academic backgrounds but there will also be people from industry as

well as government administrators,î says Kimura. ìOur biggest challenge

will be to formulate ways to ensure that physicists, medical doctors, and

chemists can communicate with investment bankers, lawyers, and patent

attorneys. They may speak different languages, but they have the same

goal of making iCON a success.î

Produced by the Science/AAAS Custom Publishing Office ADVERTORIAL

Hiromichi Kimura Tomohiro Anzai

ìWe will not only have people from different academic

backgrounds but there will also be people from industry as

well as government administrators.î óHiromichi Kimura

Academia and National InstitutesThe University ofTokyoTokyo Institute ofTechnologyTokyoWomenís Medical UniversityNational Cancer Center (Tokyo)Central Institute for Experimental AnimalsKeio University (Tokyo)

Stanford University (USA)Karolinska Institutet(Sweden)

IndustryFujifilm CorporationNikon CorporationNanoCarrier Co., Ltd.

Participants in the innovation CenterOf Nanomedicine include:

Artistís Impression of the innovation Center Of Nanomedicine (iCON)

Page 5: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Cut smarter.Restriction enzymes from NEB –

now with CutSmart™ Buffer

You make smart choices every day. Why stop there? The choice to use

restriction enzymes from New England Biolabs is now even easier.

• Choose from > 200 restriction enzymes supplied with a single buffer

• Simplify your double digest reactions

• Reduce your pipetting steps by no longer having to add BSA

Now, that’s Smart!

Explore the smarter choice at

NEBCutSmart.com

Page 6: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Want towin a ratherspecial prize in Stockholm,Sweden thisDecember?Winner’s essay published in the journal Science

$25,000 dollars grand prize

Awards held in Stockholm in December

Henrik

Trygg/Im

agebank,Sweden

Tis December a rather special prize will be awarded in Stockholm, Sweden. Te journal Science and SciLifeLab

have come together to recognize and celebrate excellence in PhD research. Te Science and SciLifeLab Prize has

been established to support young scientists at the start of their career.

“Science has never been more exciting and, as leaders in science, we need to support

and encourage young researchers today and tomorrow. Tis prize is a way of doing just that.”Professor Mathias Uhlén, Director SciLifeLab

Te grand prize winner of this major global award will have their essay published in the journal Science and receive

$25,000. Tree runners up will receive a combined total of an additional $10,000 in prize money.

Te prizes will be presented in Stockholm, Sweden in the middle of December 2013.

To enter

You must be a recent Ph.D. graduate (awarded between January 1, 2011 and December 31, 2012).

Submissions must be in the form of a 1000 word essay, in English, on your thesis, highlighting the signif-

cance of its contribution and overall implications in the feld. Te four submission areas for this prize are:

(1) Genomics / Proteomics / Systems Biology (2) Developmental Biology (3) Molecular and Cellular Biology

(4) Environmental Life Science.

Te deadline for submissions is August 15, 2013. Te overall winning essay will be published in Science.

For further details and to enter, please go to: www.sciencemag.org/scilifelabprize

For over 130 years the

journal Science has been the

world’s leading journal of

original scientifc research,

global news and commentary.

SciLifeLab is a collaboration

between four universities in

Stockholm and Uppsala, Sweden,

and is a pioneering center for

large-scale biosciences with a

focus on health and

environmental research.

With the kind support

of the Knut and Alice Wallenberg

Foundation.

Page 7: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

P-1000

NextGeneration

MicropipettePuller

The latest in micropipette pulling technology!

FEATURES

• Color touch-screen interface

• Safe heat mode to protect and extend filament life

• Pipette Cookbook program directory

• Line repeat mode simplifies programming

• Glossary with micropipette and puller terminology

• Copy & Paste function for writing new programs

• Two symmetrical pipettes with each pull

• Memory storage for up to 100 programs

PHONE: 415.883.0128 | FAX: 415.883.0572

EMAIL: [email protected] | WWW.SUTTER.COM

Science &

Diplomacy

provides an open

access forum for

rigorous thought,

analysis, and

insight to serve

stakeholders

who develop,

implement, or

teach all aspects

of science and diplomacy. Learn more about the latest

ideas in science diplomacy and receive regular updates

by following@SciDip on Twitter and registering for

free at www.sciencediplomacy.org/user/register.

www.ScienceDiplomacy.org

Science & Diplomacy is published by the Center for Science

Diplomacy of the American Associaton for the Advancement of

Science (AAAS), the world’s largest general scientfc society.

The Leading Journal of Cell Signaling

• Peer-reviewed Research Articles and Resources

• Perspectives, Reviews, Protocols, and an interactive Database of Cell Signaling

• Recommend Science Signaling to your institution’s library

ScienceSignaling.org/recommend

ScienceSignaling.org

Page 8: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Eppendorf®, the Eppendorf logo and Eppendorf Tubes® are registered Trademarks of Eppendorf AG, Germany.

All rights reserved, including graphics and images. Copyright © 2013 by Eppendorf AG.

50 years of experience in highest quality

Eppendorf consumables are the result

of 50 years constant improvement and

development. With the new Eppendorf

Tubes® 5.0 mL a new tube format in the

medium volume range will complete the

legendary Eppendorf Tubes family.

Laboratory processes will become

easier and more convenient.

Purest assay results are no coincidence:

> Unique features to make every day

routines faster and easier

> Minimized risk of chemical leaching

from consumables

> Purity grades tailored to even the

highest requirements

www.eppendorf.com/consumables

Eppendorf Consumables—

it’s Your sample

Future included

Page 9: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

P-1000

NextGeneration

MicropipettePuller

The latest in micropipette pulling technology!

FEATURES

• Color touch-screen interface

• Safe heat mode to protect and extend filament life

• Pipette Cookbook program directory

• Line repeat mode simplifies programming

• Glossary with micropipette and puller terminology

• Copy & Paste function for writing new programs

• Two symmetrical pipettes with each pull

• Memory storage for up to 100 programs

PHONE: 415.883.0128 | FAX: 415.883.0572

EMAIL: [email protected] | WWW.SUTTER.COM

Science &

Diplomacy

provides an open

access forum for

rigorous thought,

analysis, and

insight to serve

stakeholders

who develop,

implement, or

teach all aspects

of science and diplomacy. Learn more about the latest

ideas in science diplomacy and receive regular updates

by following@SciDip on Twitter and registering for

free at www.sciencediplomacy.org/user/register.

www.ScienceDiplomacy.org

Science & Diplomacy is published by the Center for Science

Diplomacy of the American Associaton for the Advancement of

Science (AAAS), the world’s largest general scientfc society.

The Leading Journal of Cell Signaling

• Peer-reviewed Research Articles and Resources

• Perspectives, Reviews, Protocols, and an interactive Database of Cell Signaling

• Recommend Science Signaling to your institution’s library

ScienceSignaling.org/recommend

ScienceSignaling.org

Page 10: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

574

Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are

featured in this space. Emphasis is given to purpose, chief characteristics, and availability of products and materials. Endorsement by Science or AAAS of any products or

materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.

Electronically submit your new product description or product literature information! Go to www.sciencemag.org/products/newproducts.dtl for more information.

��������������

���,��+)��,���� ��,���,����,)*+,���,��, �������,������ ,���,�������,��+)�,���������,������ �,��,��,��,��,)*+,�������� ,����!����",��,������! �����,�#*+, "��� � ,����,����,�����,��,������!����,�� �������, �������,�)*+!��� ,���,�������,�����,)*+, ��!��� ,�������,���,�����, �����,��������,�������� , ���,� ,������!��$��%,������!��������,�� ��,��,�� �,������,���� ���"&,���,��+)�,�������,�����",����� ,������,��,���,)*+, �����%,�����",�����'��,���,� (,��, �����, �� ,��,�� ����,���,������,�� ���&,���,��������,���������,��,(��, ������ ,��,����,�� ,��,���,�#*+,����,�� �, ���, "��� � ,����� ,� ����� ,��,�����,���,����,�������,�,�, �!���,����%,�������,�, ������,������,�������, ���&,���,��+)��,���� ��,���,����,)*+,���,��,��������,����� ,���,���������� ,��,)*+!���,��,������,��",���,����� ,��,�����,)*+,����,��,�����,������� ��,�,��,���, ���� ,����,��,��,����,���"���"�����,�)*+&,��������� �������

��� ����� ��������� ///���!�� �����!� �/

���������������/ ���/ &��������/ �&�,/ .��/ &����/ ���/ ����/ �������/ � �/ ����/��� ������/���������/� �������/�����/������ �/��&�,�/������!/&�����/���/ �� ��/ � �/ ����������/ ���/ �������������/ ���/ ���/ ��!�! / �'(,�/ ���/� �/��/��������/ ������/ �����/��/�/)%�����/�����/� ���� /�����������/���/������ ������/�������/ �/������/���/�� ��/�� �/�������/� �# /���/�����������/���/������ �/����!/&��������/�&�,/.��/&����/ ����/��/������/ ���� �/� �/����/��������� �/����/��������/�����/���������/ �/���� /���/�/������� �/ �/-��/���/���� �����/����/�/����/�/����/��� ������/����/������ �/��������!/.�������/���/����/ �/����/����������/�&�,/���/����������� /�/�����/ �/������/���* �/�� ��/� ��������� �/���/�������� /��������/�� �����"��/������/�/)%�����+����/�����!/$ �/������ ���/����������� /���������/������������/� ������� �/���/�� /��/ ������/ �/���/���/����� /���������/���/�����/ �/���/����/���/��/���� ����/������/�/�����/���!/���� ��������������� �������������������� """�������������

��������������������

���" ������" ��������" ����������" ���" ��������" ��" ������" �"���������" ��������" ��" �������" ���" ������� " ��� �����" ��" �������"���" ����������" ��" ��������" ��" ������" �" ���� ���" ���" ��" � �����"��������" ������� �"�������" ���" ���"���������"��"��������" ���"����"�����������" ���" ������ �" ������" �" ���" ��" ���" ��� " ���" ����"���" ���������" ��" ��������" �����������" ��" �� " ��" ���" ���������"��" ��������" �" �� �� �" ���� �" �����" �������" ����" �����" �� �����"�� �" ��" �������"!� �" �����" ���" ���� �" ���������" ��" ��������" ����"�� ��" ���" �" ���" ����" ��" ��" �����" �" ���" ��" ��������" ���� ��"��������"���" ���������" ���� ���" ������� �" �������" ���" ���������" ��"�������" ��������" ���"�����"���" ������� " ������" �" ���" ��" ��� ���"�"��������"��������"���"��������"����������"���"�� ����"���"��"���"������"���� ��"�� ������

����������������� � ***��� ���� ���� ���$"�����*

���������������������������*������*�&*"���*�������*#���*��*��������*������*���������*���!�� ���*����* ��*�()* ��������� *���*��� �* ���������* ������*�&*"���*�������*#���*��*�*�������*��*�����*������*���*������*�������*���*�������*���*���������*��*�()*���� �* ������*���� ��*������� ��*���������* ���������*���� �� *%��* ���*������*��* ���*���*!�* ��* ��* �������*������ ��*'����*���*������*������*�&*������*�����*��� �*���*� *������*���������*��������*�*�*��������*����*���*�*�����������*���*��*��������*���*�����*��� �* ���* �������* ������*���������*����������� *���*�����*��� �*�� ���*�����* �������*����*���� ��*���*������*������ *)*����*��*������*�&*�������*!��*����*�� �����*��� ��*���*����*���*��� ������*�*��� �*��*�� �� ��*������*���������*���������� *%��*���*������*��������*���*�����������*���*��*�������*��������*� *� ��*�*����*������� ���* ������* ���������*���!� ��*���*������* �������* ��������*�������*�������� *�������� ��

������������� �� ������ ��� �����������������

������������������

���31�.�����30 ��3�12����3��3� ����3���������3��3���������� ��3��� ����33����3�� 3���33����� 3���3 3�������3���3� ��3����3,3�3��3,3/�3��3�12!323�� ��� ��� 3 ��������3 �"�3 �������3 ��������3 �3 ���3 � � ����3 ��3 ��3 ��3 +(3 ����3 � ����3� ������3� ��� ��3��������������3 ���� ���!3���31�.�����30 ��3�12����3��3�3�� �3���3���3���3�����3�12 3$$*�3� ����� 3���*3�12 3 �3�������3��� �3� �����!3���3#�3 ���3�� �����3�� ���32� ����3�� ��3��������� 3������3�������3 �� ��3 �������3 �3 �������3 3 ��� ��3 �����3���3 3 � ����3 �����3 ��3����3�������3�� ��!��������������

$��3��%3&&&�)'&�))-( ���!���������!���

2 AUGUST 2013 VOL 341 SCIENCE www.sciencemag.org/products

�������� ��������������������

������������������������ ������������ ������������������������ �������

Page 11: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

For your career in science, there’s only one

A career plan customizedfor you, by you.

Visit the website and

start planning today!

myIDP.sciencecareers.org

In partnership with:

I N D I V I D U A L

D E V E LO PM E N T

P L A NIDPmy

Careers

Overview

Setting Goals

Skill Goals

Career Advancement

Goals

Project Goals

Mentoring Team

myIDP Summary

Consider Career Fit

Read About Careers

Attend Events

Talk to People

Choose a Career Path

Skills Assessment

Interests Assessment

Values Assessment

Overview Summary

Personal Information

Development Plan

Career Exploration

Assessment

Recommended by leading professional societies and endorsed by the National Institutes of Health,

an individual development plan will help you prepare for a successful and satisfying scientific career.

In collaboration with FASEB, UCSF, and the Medical College of Wisconsin and with

support from the Burroughs Wellcome Fund, AAAS and Science Careers present

the first and only online app that helps scientists prepare their very own

individual development plan.

myIDP.sciencecareers.org

Page 12: Submit your manuscripts at ://science.sciencemag.org/content/sci/341/6145/local/advertising.pdfat KING SKYFRONT and iCON will require good communication skills between project members.

Key applications:

• Cancer Biology

• Stem Cell Research

• Developmental Biology

• Neurobiology

• Immunobiology

• Lentivirus Production

• CHO Cell Protein Production

Don’t let old toxic transfection technology

get in the way of your science.

FuGENE® HD provides the

power to transfect

virtually any cell type

while maintaining

biologically relevant

cell signaling responses.

To discover the power of FuGENE® HD for your biology, request a free sample at

www.promega.com/pathwaybiology

In this BaF3 cell model of NF-kB luciferase induction, only

FuGENEÆ HD and FuGENEÆ 6 are able to create a usable assay.

10

81

8M

A

80000

RLU

FHD

F6

LTX+

L2K

60000

40000

20000

0

0–6 – 4 –2 2 4

FuGENE®

HD

FuGENE® is a registered trademark of Fugent, LLC.

©2013 Promega Corporation. All rights reserverd. 4882